Targeting immune cells in vaccination

AbVision announces first-in-class active targeting vaccine candidate for COVID-19

DDNews Staff
MILPITAS, Calif.—Biopharmaceutical company AbVision Inc. announced May 1 that the company has developed a first-in-class COVID-19 vaccine (AVI-205) with an active targeting feature, powered by its patented ImmunoBuster-IITM Active Targeting Vaccine Platform.
 
This novel COVID-19 vaccine actively targets immune cells upon injection as compared to the passive diffusion mechanism of traditional vaccines, according to AbVision, generating strong SARS-CoV-2 S1-hACE2 neutralizing immune response in less than a week as compared to a two weeks similar response from traditional vaccines.
 
The company has now successfully completed preclinical studies and generated what is says are promising data. As a result, this novel COVID-19 vaccine candidate is now available for out-licensing and collaborations for downstream development and clinical studies, according to AbVision.
 
The company’s ImmunoBuster-II Active Targeting Vaccine Platform is, as described by AbVision, “a first-in-class potent immune activator with targeting feature, created on top of the innovation of the Company’s renowned ImmunoBuster-ITM technology. Vaccines powered by ImmunoBuster-IITM can elicit robust isotype switched IgG response in less than a week and maintain long-lasting IgG response for more than three weeks post vaccination.”
 
Reportedly, ImmunoBuster-IITM can work synergistically with essentially all commercially available vaccines to elicit faster and stronger neutralizing immunity than current vaccinations.

DDNews Staff

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022